A detailed history of Swiss National Bank transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Swiss National Bank holds 43,000 shares of MLTX stock, worth $2.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,000
Previous 30,900 39.16%
Holding current value
$2.34 Million
Previous $1.36 Million 59.65%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$40.15 - $55.4 $485,815 - $670,340
12,100 Added 39.16%
43,000 $2.17 Million
Q2 2024

Aug 08, 2024

SELL
$38.43 - $48.6 $169,092 - $213,840
-4,400 Reduced 12.46%
30,900 $1.36 Million
Q4 2023

Feb 06, 2024

SELL
$36.35 - $63.02 $163,575 - $283,590
-4,500 Reduced 11.31%
35,300 $2.13 Million
Q3 2023

Nov 08, 2023

BUY
$48.35 - $61.26 $1.92 Million - $2.44 Million
39,800 New
39,800 $2.27 Million

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $2.01B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.